adamantane has been researched along with Diabetic Cardiomyopathies in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, DD; Bhatt, DL; Braunwald, E; Gurmu, Y; Johanson, P; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Sabatine, MS; Scirica, BM; Wilding, JPH; Wiviott, SD | 1 |
| Chu, C; de Vries, F; Kothny, W; Lopez-Leon, S; Schlienger, R; Serban, C; Williams, R | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jiang, C; Li, X; Liang, G; Sa-Nguanmoo, P; Tanajak, P; Wang, X | 1 |
| Bajaj, M; Birnbaum, Y; Perez-Polo, JR; Yang, HC; Ye, Y | 1 |
| Bhatt, DL; Braunwald, E; Im, K; Kanevsky, E; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Sjöstrand, M; Stahre, C; Steg, PG; Udell, JA | 1 |
| Liu, L; Wang, DW; Wang, K; Wang, P; Wang, W; Wen, Z; Wu, L | 1 |
1 trial(s) available for adamantane and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Incretins; Male; Renal Insufficiency, Chronic | 2018 |
5 other study(ies) available for adamantane and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Topics: Adamantane; Aged; Benzhydryl Compounds; Clinical Decision-Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Health Status; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study.
Topics: Adamantane; Adult; Aged; Cardiotoxicity; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Europe; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Retrospective Studies; Vildagliptin | 2017 |
Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diabetic Cardiomyopathies; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fibroblast Growth Factors; Gene Expression Regulation; Heart Rate; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mitochondria, Heart; Nitriles; Obesity; Prediabetic State; Pyrrolidines; Rats; Rats, Wistar; Recombinant Proteins; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Vildagliptin | 2017 |
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Topics: Adamantane; AMP-Activated Protein Kinases; Animals; Apoptosis; Benzhydryl Compounds; CARD Signaling Adaptor Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fibroblasts; Fibrosis; Glucosides; Hypoglycemic Agents; Inflammasomes; Inflammation Mediators; Kidney Tubules, Proximal; Male; Mice, Inbred C57BL; Mice, Obese; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Ventricular Function, Left | 2017 |
Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha | 2018 |